Puberty
Methodology & AI Transparency ⓘ
Puberty Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Puberty is the time in life when a boy or girl becomes sexually mature.
- 2 Real-world patient consensus: Clinical coding for Puberty uses ICD-10 L70.9 across Skin & Dermatology specialty care.
- 3 Typical cash cost range: Differential triage of Puberty (L70.9) utilizes or targeted biologics [Puberty L70.9].
- 4 Top reported side effects / signs: Longitudinal Puberty monitoring tracks Affected Body Surface in Puberty (L70.9: Area (BSA /) toward Clear or Almost Clear (IGA 0–1) (L70.9).
Ask our AI Specialists anything about Puberty
What Is Puberty?
Puberty is the time in life when a boy or girl becomes sexually mature. It is a process that usually happens between ages 8 and 13 for girls and ages 9 and 14 for boys. It causes physical changes and affects boys and girls differently. In girls: The first sign of puberty is usually breast development. Then hair grows in the pubic area and armpits. Menstruation (or a period) usually happens last. In boys: Puberty usually begins with the testicles and penis getting bigger. Then hair grows in the pubic area and armpits. Muscles grow, the voice deepens, and facial hair develops as puberty continues. Both boys and girls may get acne.
Pathophysiology, Underlying Causes & Clinical Presentation
In Puberty (L70.9), physiological disruption stems from cutaneous immune skewing in Puberty (L70.9: (Th2/IL-4/IL-13 in atopic), Cross-referenced with NIH MeSH (Puberty), informing Dermatology: Acne, Eczema, Psoriasis & Rosacea protocols that track Fasting Lipids & in Puberty (L70.9: ALT (if systemic) (Within baseline reference limits (L70.9)).
Common Symptoms & Clinical Signs
- • The first sign of puberty is usually breast development
- • Then hair grows in the pubic area and armpits
- • Presentation of Puberty (L70.9): recurrent flares triggered in Puberty (L70.9: by UV exposure,)
- • Secondary Puberty clinical sign: persistent erythematous plaques, in Puberty (L70.9: scaly patches, pruritic)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Puberty Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L70.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Affected Body Surface in Puberty (L70.9: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L70.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Puberty (L70.9: ALT (if systemic) | Within baseline reference limits (L70.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Puberty (L70.9: & hs-CRP) | 25(OH)D 40–65 ng/mL (L70.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Puberty
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Nafarelin Acetate Synarel • RxCUI 1797878 | Gonadotropin Releasing Hormone Receptor Agonist | 79% | $1.7800 | $ 80.59 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Puberty)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Microencapsulated Benzoyl Peroxide and Tretinoin for the Treatment of Acne All treatments were safe with comparable skin tolerability. Skinmed • 2020-01-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 33397563 ↗ |
| Hypogonadism in male and female: which is the best treatment? A condition of hypogonadism can underlie different etiologies involving the hypothalamic-pituitary-gonadal axis at different levels. Minerva pediatrics • 2021-12-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 34309345 ↗ |
| Can This Approach Help? Inside the Latest Research on Effectiveness of a Ceramide-Based Lamellar Emulsion on Skin Barrier Function in Short-term use of the emulsion improved barrier function and may help reduce occupational skin damage in perioperative nurses. AORN journal • 2026-11-15 • Randomized Controlled Trial | N = 18 | 82/100 | PMID 42949579 ↗ |
| Can This Approach Help? Inside the Latest Research on Fixed Dosing of Leuprolide Acetate, a GnRH Agonist, in Children with Central The developed model adequately characterized leuprolide how the body absorbs the medicine in pediatrics. Paediatric drugs • 2026-05-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 41824265 ↗ |
| Can This Approach Help? Inside the Latest Research on Impaired pubertal development and testicular hormone function in males with The hormonal level assessment of testosterone at baseline and at 24, 48 and 72 h after hCG stimulation showed no significant differences between the groups studied. Blood cells, molecules & diseases • 2015-01-15 • Randomized Controlled Trial | N = 15 | 82/100 | PMID 25190051 ↗ |
Puberty Patient Community & “People Like Me” Threads
Filter Puberty community threads and patient logs by age, biological sex, dosage, and treatment duration.